Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer - Test2 - elhamkhani - TriplyDB

Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer

Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer

http://www.wikidata.org/entity/Q36840255

about

Dinosaurs and ancient civilizations: reflections on the treatment of cancer Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy TGF-β - an excellent servant but a bad master Epigenetic mechanisms in cancer: push and pull between kneaded erasers and fate writers Neoplasia: the second decade.ChIP-seq defined genome-wide map of TGFβ/SMAD4 targets: implications with clinical outcome of ovarian cancer.An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Identification of candidate epigenetic biomarkers for ovarian cancer detection.Seed in soil, with an epigenetic view Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer.Decitabine reactivated pathways in platinum resistant ovarian cancer.Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer.Epigenetic regulation of cancer-associated genes in ovarian cancer.Hypermethylation of the TGF-β target, ABCA1 is associated with poor prognosis in ovarian cancer patients Epigenomics and ovarian carcinoma.Epigenomics of ovarian cancer and its chemoprevention.Human ortholog of Drosophila Melted impedes SMAD2 release from TGF-β receptor I to inhibit TGF-β signaling Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer Epigenetic silencing of the NR4A3 tumor suppressor, by aberrant JAK/STAT signaling, predicts prognosis in gastric cancer.Partial epithelial-mesenchymal transition in keloid scars: regulation of keloid keratinocyte gene expression by transforming growth factor-β1 A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.Minireview: epigenetic changes in ovarian cancer.The War on Cancer rages on.Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy.Modulation of gene expression in ovarian cancer by active and repressive histone marks.Caffeic acid phenethyl ester activates pro-apoptotic and epithelial-mesenchymal transition-related genes in ovarian cancer cells A2780 and A2780cis.Aberrant methylation and decreased expression of the TGF-β/Smad target gene FBXO32 in esophageal squamous cell carcinoma.Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29.Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma.MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.Preliminary Study of the Role F-Box Protein 32 (FBXO32) in Colorectal Neoplasms Through the Transforming Growth Factor beta (TGF-β)/Smad4 Signalling Pathway.

P2860

Q24628746-A8CFD5C9-AC56-4661-9C4F-40CDA56102CA Q26769604-38B1CDFA-9D36-4217-B8E7-129AEA877B44 Q27025590-4F13847E-304E-4C2D-9150-E64F0A8CF8FD Q28082510-CA627814-F9C3-44A1-BC54-11E16B8FE916 Q30484000-3BE22F83-D62A-471F-A60A-9EFF5E62D332 Q31028613-BFEBE615-DE1E-4A1B-9847-8C14059DE8DA Q33483669-4B0155C1-A8CE-4FF4-BB48-FB01B1849AE7 Q33621141-DB95710D-A84E-47DB-ABC0-AD32DF68B968 Q33690321-D8A5D8DE-AC57-4722-9314-09BC73AEC360 Q33690825-CD94FFB8-8119-4886-8BDB-428B66BE2608 Q33754753-D04958E6-B6BE-4826-8860-B06F5BCF2638 Q33788703-2F9659CA-01DB-40E2-B494-1C8266E5613E Q33976957-34083507-03F6-4C95-93A7-2650BF950D36 Q34621606-5A692819-B164-4C28-BCC1-E6924220DE2F Q34874813-B68897A4-B446-46D6-B7BE-6CD31CDE22A3 Q35016196-32E444F6-7D7D-4DED-8DB8-48A22E83B435 Q35636575-CE0A7210-60A0-4D8E-B476-77740ACE42AE Q35711392-38017424-7397-4326-A110-081FAD410C27 Q35740320-3B65A234-A326-468C-B901-2121082956C1 Q35935011-705C828E-F05F-428F-83BE-CD594BB0B09D Q35985483-336BD260-3C2A-40D4-84DE-095FE3E2DE00 Q37177069-0D999B91-6C8C-42F0-AFDA-A9C633489AA7 Q37195998-1EACF080-1F04-48F1-91F9-BAB1C2308810 Q37200466-2D7CC18D-F093-4198-B2AA-8E992A058D8E Q37328836-54C2B61A-C5BC-4622-A990-442FAF5F0E05 Q37478602-E54C7FD2-A27B-4733-84AE-83FD3BA7B751 Q37702543-F3A960CE-A002-453C-A831-CA59693635DB Q37798252-0CB436DB-BFC5-4938-8447-07011C4D45C9 Q37962015-0C9620DB-249B-461F-9591-E892602D0E5A Q38797274-09BBC1E0-5743-4982-A0D3-E80F05D9B203 Q38998339-BC8E5345-2344-4511-9496-B5F7C76F5743 Q39084579-299DECBC-A56B-4000-AAEA-0FEA2F46ABEB Q47099168-E14A8630-920B-40EE-8C44-C0DE126891AE Q47939839-04782DB4-642F-4286-B71E-78D398338ABB Q49716199-CEBA97CF-876E-4A23-B473-50724B0B2559

P2860

Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer

http://www.wikidata.org/entity/Q36840255

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Aberrant transforming growth f ...... on of ADAM19 in ovarian cancer

@en

type

label

Aberrant transforming growth f ...... on of ADAM19 in ovarian cancer

@en

prefLabel

Aberrant transforming growth f ...... on of ADAM19 in ovarian cancer

@en

P1433

Q36840255-89CFB07E-5E92-4726-B079-CD46632B2929

P1476

Q36840255-2222D601-0BCA-439A-8EA3-246AA14A0C7E

P2093

Q36840255-0C12F948-CF90-4080-A728-BACBEF8A15B3

Q36840255-3A9CDC06-0018-495F-A634-CC845B8EEC7D

Q36840255-4BB69D9B-2010-4C92-8459-2CAB1C4E3AC3

Q36840255-71F27B14-2657-4F55-B5B4-C99F43767A84

Q36840255-786F7394-4373-4CE6-9B0F-19E7F76ACDB8

Q36840255-84446EBD-4BEB-4A87-9043-97D962565726

Q36840255-91D75FD7-2CA2-4A82-B8DC-384F83E0BB67

Q36840255-97FAAC63-985C-4255-8021-7370DAC817B0

Q36840255-BBE2D1F5-3C3F-4342-9383-3EE99D956002

Q36840255-C9DC6F39-6BFE-4522-BC65-FDFC5930C14D

P2860

Q36840255-00DBE056-5C27-4F77-BA1E-BE957977B672

Q36840255-01B8CB09-C946-4669-A862-4A43EF8633B5

Q36840255-0317DC52-0AE1-4D8E-89C2-001015E57489

Q36840255-0CE4FF6F-D8C0-4456-A744-3C340A096F20

Q36840255-0CF58FBD-A2A5-4555-B249-D57F4763A8A3

Q36840255-0E5B3E3D-5A1B-4737-9DE4-C3BAC3325D7D

Q36840255-0E721397-BB94-4DF5-AF31-9D92885F5AA4

Q36840255-0FE3AE3A-A541-4C5F-82F5-1D0997077404

Q36840255-1DE2081E-3EEC-4776-A464-2CA21DC60A90

Q36840255-2E42FFD6-E37E-4C5A-A135-633F72A9DE8F

P304

Q36840255-98B2FE3D-1062-4DDF-A415-AF36F487DD97

P31

Q36840255-688B997F-C07B-47AC-88E9-D6D09DB30CAC

P356

Q36840255-DBEF624B-17F6-45CD-8946-388A4244E2F5

P433

Q36840255-4FE55FF4-44A1-4179-AD13-B667F83FD1FA

P478

Q36840255-4706AB99-A35C-4BDD-8BFE-FB3E892223AB

P577

Q36840255-5333CB86-49E6-44FD-9DD7-2D346CE04541

P5875

Q36840255-67C44282-0532-4695-9E25-17546FEFB0AC

P698

Q36840255-6626D658-CD65-4F37-BBFF-DC0DC8CC6FD9

P921

Q36840255-8215405C-35E6-4B5E-9D1E-17E04CE0E4E1

P932

Q36840255-828EB2FD-BF1A-4A96-9DC1-CECB7BA08285

P356

P1433

P1476

Aberrant transforming growth f ...... on of ADAM19 in ovarian cancer

@en

P2093

Alfred Sl Cheng

http://www.w3.org/2001/XMLSchema#string

Chieh-Ti Kuo

http://www.w3.org/2001/XMLSchema#string

Corinna Hartman-Frey

http://www.w3.org/2001/XMLSchema#string

Daniel Deatherage

http://www.w3.org/2001/XMLSchema#string

Huaxia Qin

http://www.w3.org/2001/XMLSchema#string

Huey-Jen L Lin

http://www.w3.org/2001/XMLSchema#string

Kenneth P Nephew

http://www.w3.org/2001/XMLSchema#string

Michael Wy Chan

http://www.w3.org/2001/XMLSchema#string

Pearlly S Yan

http://www.w3.org/2001/XMLSchema#string

Ramana V Davuluri

http://www.w3.org/2001/XMLSchema#string

P2860

Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility

ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease

The fundamental role of epigenetic events in cancer

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

The role of chromatin during transcription

Roles of Meltrin beta /ADAM19 in the processing of neuregulin

Epigenetic regulation of the dendritic cell-marker gene ADAM19

ADAMs: key components in EGFR signalling and development

Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium

TGF-beta signaling in tumor suppression and cancer progression

P304

908-919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.08540

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258022179

http://www.w3.org/2001/XMLSchema#string

P698

18714391

http://www.w3.org/2001/XMLSchema#string

P921

P932

2517635

http://www.w3.org/2001/XMLSchema#string